Sartorius Stedim Biotech (DIM) AI Stock Analysis

• Market Cap: €19.50B
• Dividend Yield: 0.34%
• Average Volume (3M): 76.48K
• Price to Earnings (P/E): 95.4
• Beta (1Y): 1.50
• Revenue Growth: 5.21%
• EPS Growth: -23.23%
• Country: FR
• Employees: 9,961
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 97,330,410
• 10 Day Avg. Volume: 73,460
• 30 Day Avg. Volume: 76,478
• PEG Ratio: 5.78
• Price to Book (P/B): 4.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 33.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €239.13
• Price Target Upside: 19.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

FR:DIM demonstrates strong financial stability with effective cash flow management and solid operating margins. Nonetheless, the high P/E ratio presents valuation concerns, and technical indicators show mixed signals. The stock's performance could be impacted by its high valuation and potential overbought condition.

Sartorius Stedim Biotech Business Overview & Revenue Model

Company Description

Sartorius Stedim Biotech (DIM) is a leading international supplier to the biopharmaceutical industry. The company specializes in the development and manufacturing of products and services that facilitate the production of biopharmaceuticals. Its core offerings include bioprocess solutions, such as filtration, fermentation, purification, and fluid management, which are essential for the efficient and safe production of medications, vaccines, and other critical therapies.

How the Company Makes Money

Sartorius Stedim Biotech generates revenue primarily through the sale of its bioprocess solutions, which are widely used in the production of biopharmaceuticals. Key revenue streams include the sale of equipment and consumables, such as filters and bags, as well as providing services like engineering and validation support. The company's earnings are significantly bolstered by long-term partnerships and contracts with major pharmaceutical and biotech companies, which rely on Sartorius Stedim Biotech's products for their manufacturing processes. Additionally, Sartorius Stedim Biotech benefits from the growing demand for biopharmaceuticals, driven by the increasing need for innovative therapies and vaccines, thereby sustaining its revenue growth.

Sartorius Stedim Biotech Financial Statement Overview

Summary

The company exhibits a solid financial profile with stable income growth, strong gross profit and operating margins, and effective cash flow management. However, there's room for improvement in net profit margin and return on equity.

Income Statement

The income statement shows a stable revenue base with a modest growth rate of 2.8% in the latest TTM compared to the previous annual period. Gross profit margin is strong at 43.9%, indicating effective cost management. However, the net profit margin is relatively low at 7.1%, suggesting potential pressure on net earnings. EBIT and EBITDA margins are healthy at 15.6% and 25.5%, respectively, reflecting robust operating performance.

Balance Sheet

The balance sheet indicates a moderate debt-to-equity ratio of 0.74, which suggests a balanced approach to leverage. Return on equity stands at 5.1%, pointing to room for improvement in generating returns from equity. The equity ratio is reasonable at 47.8%, reflecting a solid equity foundation. Overall, the balance sheet is stable, though the company could enhance its ROE.

Cash Flow

Cash flow analysis reveals a significant 22.8% growth in free cash flow over the previous annual period, highlighting improved cash generation. The operating cash flow to net income ratio is strong at 4.3, indicating effective cash conversion. The free cash flow to net income ratio of 2.9 further underscores efficient cash flow management. Overall, the company demonstrates robust cash flow performance.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.86B	2.78B	2.78B	3.49B	2.89B	1.91B
	Gross Profit
1.25B	1.21B	1.23B	1.83B	1.55B	1.00B
	EBIT
446.10M	370.60M	484.50M	995.20M	683.30M	471.81M
	EBITDA
730.20M	670.50M	755.70M	1.35B	811.96M	623.79M
	Net Income Common Stockholders
204.30M	175.10M	309.70M	876.10M	414.40M	335.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
695.10M	688.80M	126.10M	133.00M	237.35M	69.61M
	Total Assets
8.44B	8.26B	7.74B	5.07B	3.95B	3.07B
	Total Debt
3.19B	2.87B	3.68B	1.14B	625.52M	586.78M
	Net Debt
2.49B	2.19B	3.57B	1.03B	401.89M	527.02M
	Total Liabilities
4.57B	4.23B	5.07B	2.55B	2.22B	1.59B
	Stockholders Equity
3.83B	3.99B	2.64B	2.45B	1.66B	1.46B
Cash Flow		Free Cash Flow
583.60M	475.30M	156.10M	181.70M	371.98M	257.69M
	Operating Cash Flow
879.50M	815.10M	629.70M	612.30M	695.97M	416.88M
	Investing Cash Flow
-296.10M	-340.00M	-2.72B	-957.50M	-465.23M	-621.12M
	Financing Cash Flow
-573.00M	84.90M	1.99B	220.70M	-71.71M	234.07M

Sartorius Stedim Biotech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 200.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DIM, the sentiment is Neutral. The current price of 200.4 is below the 20-day moving average (MA) of 202.10, above the 50-day MA of 190.45, and above the 200-day MA of 188.83, indicating a neutral trend. The MACD of 4.05 indicates Positive momentum. The RSI at 53.74 is Neutral, neither overbought nor oversold. The STOCH value of 20.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:DIM.

Sartorius Stedim Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	76 Outperform	$111.94B	20.23	7.34%	4.14%	-4.62%	2.88%
VIRP	74 Outperform	€2.61B	17.61	14.95%	0.43%	12.07%	20.48%
IPS	74 Outperform	€1.96B	9.54	13.66%	3.65%	2.13%	29.48%
DIM	64 Neutral	€19.50B	95.45	5.24%	0.34%	5.21%	-23.23%
ALCLS	57 Neutral	$97.90M	―	-58.55%	―	833.95%	38.17%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%

Sartorius Stedim Biotech Corporate Events

Sartorius Stedim Biotech Releases 2024 Universal Registration Document

Sartorius Stedim Biotech has announced the availability of its 2024 Universal Registration Document, which includes the group’s business development details for 2024 and the 2025 forecast. This document, now accessible on their investor relations page, also contains the consolidated financial statements for the year ended December 31, 2024. The release of this document provides stakeholders with comprehensive insights into the company’s financial and strategic positioning, potentially impacting investor confidence and industry standing.